A5010814818- Pain Management and Treatment
- Dermatological and COVID-19 studies
- Rheumatoid Arthritis Research and Therapies
- S100 Proteins and Annexins
- COVID-19 Clinical Research Studies
- Spine and Intervertebral Disc Pathology
- Pain Mechanisms and Treatments
- Long-Term Effects of COVID-19
- Acute Myocardial Infarction Research
- Bone and Joint Diseases
- Lipoproteins and Cardiovascular Health
- Biomarkers in Disease Mechanisms
- Viral Infections and Immunology Research
- Systemic Lupus Erythematosus Research
- Myofascial pain diagnosis and treatment
- Sepsis Diagnosis and Treatment
- Musculoskeletal synovial abnormalities and treatments
- Laser Applications in Dentistry and Medicine
- SARS-CoV-2 and COVID-19 Research
- RNA regulation and disease
Université Grenoble Alpes
2015-2020
Centre Hospitalier Universitaire de Grenoble
2014-2017
Hôpital Nord
2017
Institut Universitaire de Recherche Clinique
2016
There is little known about the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). We examined epidemiological characteristics associated severe disease, then death. also compared mortality between hospitalised for COVID-19 without iRMD.Individuals suspected iRMD-COVID-19 were included in this French cohort. Logistic regression models adjusted age sex used to estimate ORs 95% CIs COVID-19. The most significant clinically relevant factors...
Growth arrest and DNA damage-inducible gene 34 (GADD34) is an inducible cofactor of protein phosphatase 1, which has important role in the unfolded response. GADD34 been shown to be necessary for type I interferon proinflammatory cytokine production response viral infection murine models. We investigate expression rheumatoid arthritis (RA), cytokines have pathogenic role. The objective this study was evaluate potential as a biomarker RA patients. report case-control on peripheral blood...
<h3>Background</h3> Cardiovascular risk (CVR) is increased in RA and should be evaluated annually. EULAR recommends using the SCORE equation to calculate risk, after applying a multiplier of 1.5 patients with who meet two following three criteria: disease duration >10 years, rheumatoid factor or anti-CCP antibody positivity, presence extra-articular manifestations. European guidelines recommend statin therapy for subjects high very i.e aged 45-65 years when CVR calculated ≥10%...